08-07-2021, 07:03 AM
(08-07-2021, 06:33 AM)fenders53 Wrote: I would be cautious chasing PFE with much money here. Sure their revenues will be amazing for 2021/22 but it's a hard act to follow. Maybe these vaccine makers do have room to go higher but some quarter soon the phase 3 stable will be what matters to the market. PFE is not a biotech startup that runs higher on phase one hopes.
This article agrees with you.
While I believe the messenger RNA vaccines will change biotech forever, the article did note that in some people it causes heart inflammation.
I will probably lead with a starter position on it (which has moved up to $3k).